Document is current
Any future updates will be listed below
-
Authors
Perica, Karlo https://orcid.org/0000-0002-3595-7596
Flynn, Jessica
Curran, Kevin J.
Rivere, Isabelle
Wang, Xiuyan
Senechal, Brigitte
Halton, Elizabeth
Diamonte, Claudia
Pineda, John
Bernal, Yvette
Gonen, Mithat
Sadelain, Michel
Brentjens, Renier J. https://orcid.org/0000-0002-3364-5388
Park, Jae H. https://orcid.org/0000-0002-2903-5130
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (T32-CA009207)
- License Information
-
More Information
Article History
Received: 10 September 2020
Revised: 21 January 2021
Accepted: 10 February 2021
First Online: 8 March 2021
Compliance with ethical standards
:
: KP discloses patent or royalties (Neximmune, Inc.) and acknowledges funding from NCI (t32-CA009207). KJC discloses consulting or advisory role (Novartis) and research funding (Juno Therapeutics). CD discloses travel accommodations and expenses from Juno Therapeutics. MG discloses consulting or advisory roles with Tesaro. IR discloses stock or ownership interest, consulting or advisory role, research funding, and patents and royalties, all from Juno Therapeutics. MS discloses consulting or advisory role (Juno Therapeutics), research funding (Atara Biotherapeutics; Fate Therapeutics; Juno Therapeutics; Takeda; Takeda; Takeda; Takeda), and patients or royalties (Juno Therapeutics). RB discloses stock and ownership interests, consulting or advisory role, research funding, and patents or royalties, all from Juno Therapeutics. JHP discloses consulting or advisory roles (Adaptive Biotechnologies; Amgen; Kite Pharma; Novartis; Pfizer) and research funding (Genentech/Roche; Juno Therapeutics).
